Senior Research Associate
Monte Rosa Therapeutics
Senior Research Associate
Monte Rosa Therapeutics
Develops targeted protein degraders for therapy
At Monte Rosa Therapeutics, we’re excited to seek a dedicated Compound Manager to join our team. You’ll play a pivotal role within our Compound Management Team, working closely with colleagues to deliver compounds in a variety of formats for the Screening Teams. Your expertise will directly support the characterization of innovative small molecule glue-based degraders and drive the advancement of our expanding pipeline. If you’re passionate about collaboration, innovation, and making a real impact in scientific discovery, we’d love to meet you.
Fluent in English, both written and spoken
Compensation: 90000 to 105000 (CHF)
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.
Explore more opportunities at Monte Rosa Therapeutics